Analysts Set Expectations for NTLA FY2027 Earnings
Equities researchers at Zacks Research issued their FY2027 EPS estimates for shares of Intellia Therapeutics in a research note issued to investors on Thursday, March 20th. Zacks Research analyst R.
TMCnet23h
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) and reminds investors ...
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc.(NTLA) Shareholders
NEW YORK, NY / ACCESS Newswire / March 23, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to ...
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The last few weeks of cascading share prices may be troublesome to most investors, but Cathie Wood doesn't mind buying during the deluge. The co-founder, CEO, and investment manager at Ark Invest has ...
TipRanks on MSN16d
Palantir, Barrick, Intuit, Intellia, Beyond: Trending by Analysts
Analysts are intrested in these 5 stocks: ( ($PLTR) ), ( ($GOLD) ), ( ($INTU) ), ( ($NTLA) ) and ( ($BYON) ). Here is a breakdown of their recent ...
The Motley Fool26d
Intellia Therapeutics Delivers a Q4 Beat
Using CRISPR/Cas9 gene-editing technology, Intellia Therapeutics develops gene-editing treatments for genetic diseases. The company's lead programs, NTLA-2001 and NTLA-2002, target transthyretin ...
Nasdaq26d
Intellia Therapeutics Doses First Patient in Phase 3 HAELO Study for NTLA-2002 and Updates on Clinical Trials and Financial Results
Intellia Therapeutics details progress in Phase 3 trials for NTLA-2002 and nex-z, anticipating key regulatory submissions by 2026. Intellia Therapeutics has announced the initiation of the global ...
Cantor Fitzgerald Forecasts NTLA FY2025 Earnings
Cantor Fitzgerald issued their FY2025 EPS estimates for Intellia Therapeutics in a research report issued on Monday, March 17th. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company ...
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Intellia Therapeutics
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hund ...
Morningstar4d
Intellia Therapeutics Inc NTLA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Nasdaq25d
Intellia Therapeutics Delivers a Q4 Beat
Intellia Therapeutics (NASDAQ:NTLA), a leader in gene-editing technology, delivered its fourth-quarter earnings results on Feb. 27. The company reported a net loss of $1.27 per share, which was ...